Medicago, GSK's Plant-Based COVID-19 Vaccine Candidate Hits 75% Efficacy Against Delta Strain

Canada-based Medicago and GlaxoSmithKline plc GSK have released Phase 3 data from their plant-derived adjuvanted COVID-19 vaccine candidate. The trial was conducted on over 24,000 subjects (adults 18 years and above) across six countries.

  • The companies found that the overall vaccine efficacy rate against all variants of SARS-CoV-2 was 71%, with the number for people with an initial seronegative status (showing no previous exposure to COVID-19) 75.6%. 
  • The vaccine works as two doses of 3.75 µg of antigen combined with GSK's pandemic adjuvant given 21 days apart.
  • The vaccine candidate demonstrated the efficacy of 75.3% against COVID-19 of any severity for the globally dominant Delta variant. 
  • Efficacy was 88.6% against the gamma variant, though it's in small numbers of people.
  • No cases of the alpha, lambda, and mu variants were observed in the vaccinated group, while 12 cases were observed in the placebo group.
  • Complete results of GSK/Medicago's phase 3 study "will be released in a peer-reviewed publication as soon as possible." 
  • Medicago will imminently seek regulatory approval from Health Canada as part of its rolling submission. 
  • Related Link: GlaxoSmithKline-Medicago's COVID-19 Vaccine Candidate Elicit Strong Immune Response.
  • Price Action: GSK shares are up 0.74% at $42.07 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefsCOVID-19 CoronavirusCOVID-19 VaccinePhase 3 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!